Belimumab Therapy in Systemic Lupus Erythematosus

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

(2012) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice

(2010) Meera Ramanujam et al.   ARTHRITIS AND RHEUMATISM

Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF

(2010) M. Ota et al.   JOURNAL OF IMMUNOLOGY

Multistoried roles for B lymphocytes in autoimmunity

(2010) Masaki Hikada et al.   NATURE IMMUNOLOGY

Impact of systemic lupus erythematosus on health, family, and work: The patient perspective

(2010) Don Robinson et al.   ARTHRITIS CARE & RESEARCH

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases

(2009) M Ramos-Casals et al.   LUPUS

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: Mortality risk and quality of life early in the course of disease

(2008) Robert Campbell et al.   ARTHRITIS AND RHEUMATISM

Prevention of murine antiphospholipid syndrome by BAFF blockade

(2008) Philip Kahn et al.   ARTHRITIS AND RHEUMATISM

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells

(2008) G. Badr et al.   BLOOD

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

(2008) E. Belnoue et al.   BLOOD

B lymphocytes - chief players and therapeutic targets in autoimmune diseases

(2008) Moncef Zouali   Frontiers in Bioscience-Landmark

Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation

(2008) Almut Meyer-Bahlburg et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

(2008) J. L. Scholz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY